# Treatments for COVID-19 and acute respiratory infections are associated with gender and comorbidities in an Italian online survey

**Authors:** Marco Leonti, Cristina Mollica, Sara Spadaccini, Laura Casu

PMC · DOI: 10.1371/journal.pone.0342466 · PLOS One · 2026-02-17

## TL;DR

An Italian online survey found that treatments for respiratory infections and COVID-19 varied by gender and health conditions, with women using more treatments and specific drugs like macrolides linked to cardiovascular risks.

## Contribution

The study reveals gender and comorbidity influences on treatment choices for respiratory infections and COVID-19 in Italy, highlighting potential risks of macrolide use.

## Key findings

- Women used more treatments than men for both respiratory infections and COVID-19, though the gender gap was smaller for COVID-19.
- Macrolide antibiotics and steroids were more common in treating COVID-19, especially among those with cardiovascular conditions.
- Patients with cardiovascular pre-conditions were more likely to use macrolides, which may increase cardiovascular risks.

## Abstract

Ministries of health need to know and understand factors affecting medical treatment choices of population subgroups, to tailor official recommendations. This study aimed to identify, quantify and compare treatments used by patients with an acute respiratory infection with and without COVID-19 during the first year of the pandemic by accounting for important factors potentially affecting treatment outcomes. With an online questionnaire, retrospective information on treatments used during events of acute respiratory infections were gathered in Italy. Logistic regression was used to detect significant associations between treatments and a set of variables including socio-demographic data, comorbidities and risk factors. We explored differences in treatments used by subjects who developed symptoms of an acute respiratory infection, with and without COVID-19. Women generally took more treatments than men for both, common acute respiratory infections and COVID-19, although, for the latter condition the gender difference in the average number of treatments was smaller. Painkillers (incl. NSAIDs) followed by antibiotics were the most frequently used drugs by both disease groups while the use of macrolide antibiotics and steroids were typical for the COVID group. Logistic regression models for COVID-19 treatments showed significant positive associations between women and the use of food supplements, depression severity and the use of ibuprofen, as well as between both, age class 50−64 and cardiovascular pre-conditions with macrolide antibiotics. COVID-19 patients were largely following official recommendations issued by the Italian Ministry of Health, using less complementary and alternative medicines when compared to common acute respiratory infections. Particularly, official recommendations suggesting the use of allegedly anti-inflammatory macrolide antibiotics for COVID-19 seem to have been followed for patients with cardiovascular pre-conditions. Considering that macrolide antibiotics augment the risk for cardiovascular death and that cardiovascular diseases are known to be a risk factor for COVID-19 related death, treating COVID-19 patients with macrolide antibiotics was probably not a great idea.

## Linked entities

- **Chemicals:** ibuprofen (PubChem CID 3672), steroids (PubChem CID 139082353)
- **Diseases:** COVID-19 (MONDO:0100096), depression (MONDO:0002050)

## Full-text entities

- **Diseases:** Obesity (MESH:D009765), tachycardia (MESH:D013610), overweight (MESH:D050177), COPD (MESH:D029424), acute (MESH:D000208), fever (MESH:D005334), osteoarthritis (MESH:D010003), liver disease (MESH:D008107), inflammation (MESH:D007249), ARIs (MESH:D012141), respiratory diseases (MESH:D012140), pain (MESH:D010146), cancer (MESH:D009369), chronic bronchitis (MESH:D029481), diabetes (MESH:D003920), inflammatory lung diseases (MESH:D008171), renal failure (MESH:D051437), emphysema (MESH:D004646), asthma (MESH:D001249), Depression (MESH:D003866), plague (MESH:D010930), heart failure (MESH:D006333), bacterial infection (MESH:D001424), pulmonary fibrosis (MESH:D011658), joint and muscle pain (MESH:D063806), viral infections (MESH:D014777), bronchiectasis (MESH:D001987), death (MESH:D003643), COVID (MESH:D000086382), infection (MESH:D007239), cardiovascular adverse effects (MESH:D002318), myocardial infarction (MESH:D009203), loss of smell and/or taste (MESH:D000086582), chesty cough (MESH:D003371)
- **Chemicals:** aspirin (MESH:D001241), essential oil (MESH:D009822), erythromycin (MESH:D004917), amoxicillin (MESH:D000658), vitamin D (MESH:D014807), Ibuprofen (MESH:D007052), azithromycin (MESH:D017963), clarithromycin (MESH:D017291), acetaminophen (MESH:D000082), zinc (MESH:D015032), oxygen (MESH:D010100), quercetin (MESH:D011794), clavulanic acid (MESH:D019818), steroids (MESH:D013256), ketoprofen (MESH:D007660), alcohol (MESH:D000438), beta-lactam (MESH:D047090), calcium (MESH:D002118), magnesium (MESH:D008274), naproxen (MESH:D009288), BuscofenAct (-), hydroxychloroquine (MESH:D006886), Macrolides (MESH:D018942), mineral (MESH:D008903), Nicotine (MESH:D009538)
- **Species:** Severe acute respiratory syndrome coronavirus 2 (no rank) [taxon 2697049], Zingiber officinale (ginger, species) [taxon 94328], Citrus x limon (lemon, species) [taxon 2708], Thymus vulgaris (common thyme, species) [taxon 49992], Curcuma longa (turmeric, species) [taxon 136217], Eucalyptus (genus) [taxon 3932], Bacteria Latreille et al. 1825 (Bacteria stick insect, genus) [taxon 629395], Homo sapiens (human, species) [taxon 9606], Melaleuca alternifolia (tea tree, species) [taxon 164405]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12912575/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12912575/full.md

## References

54 references — full list in the complete paper: https://tomesphere.com/paper/PMC12912575/full.md

---
Source: https://tomesphere.com/paper/PMC12912575